Scientific Publications
and Presentations
Innovation and discovery drive our business. We are proud to share publications and presentations about our products and investigational pipeline candidates.
Please Select Year
Caring for Patients Receiving 177Lu-DOTATATE, Lutathera®: A Treatment of Hope for Patients With Gastroenteropancreatic Neuroendocrine Tumors
Hromadik LK, Sturges L. J. Radiol. Nurs. (2019).
A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radioisotope Therapy for Patients With Neuroendocrine Tumors
Kasi PM, Maige CL, Shahjehan F, Rodgers JM, Aloszka DL, Ritter A, Andrus ML, Mcmillan JM, Mody K, Sharma A, Jain MK. Front. Oncol. (2019).
Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors
El Haddad G. Dig Dis Interv. (2018).
Impact of Liver Tumor Burden on Therapeutic Effect of 177Lu-DOTATATE Treatment in NETTER-1
J. Strosberg, A. Hendifar, J.C. Yao, M. Kulke, T. O’Dorisio, M. Caplin, R.P. Baum, P. Kunz, T. Hobday, E. Wolin, E.S. Mittra, K. Oberg, P. Ruszniewski, B. Polack, B. He, D. Barton, P. Santaro, E. Krenning.
EANM 2018: NETTER-1 Study Abstracts
Impact of Baseline Liver Tumor Burden on Treatment Outcomes with LUTATHERA® in the NETTER-1 Study (First author: Professor Jonathan Strosberg) -
Renal Protection during LUTATHERA® Treatment Using Lysine and Arginine Solutions (First author: Professor Lisa Bodei) -
Dosimetry of LUTATHERA® in Patients with Advanced Midgut Neuroendocrine Tumors: Results of the Phase III NETTER-1 Sub-Study (First author: Professor Lisa Bodei).
The recent European approval of lutetium (177Lu) oxodotreotide increases treatment options for gastroenteropancreatic neuroendocrine tumors
Caplin M. Int J Endocrine Onc (2018).
Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 Study: 177Lu-DOTATATE (Lutathera®) vs high dose octreotide in progressive midgut neuroendocrine tumors
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Hobday T, Hendifar A, Ravasi L, Oberg K, Ruszniewski P, Krenning E, on behlf of the NETTER-1 study group.
First Update on Overall Survival, Progression-free Survival, and Time-to-deterioration of Health-related Quality of Life from the NETTER-1 Study: 177Lu-DOTATATE (Lutathera®) vs high dose octreotide in progressive midgut neuroendocrine tumors
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Hobday T, Hendifar A, Lopera Sierra M, Oberg K, Ruszniewski P, Krenning E, on behlf of the NETTER-1 study group.
Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-DOTATATE (Lutathera®) vs High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Hobday T, Hendifar A, Oberg K, Ruszniewski P, Krenning E, on behlf of the NETTER-1 study group.
68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology
Dalm SU, Bakker IL, de Blois E, Doeswijk GN, Konijnenberg MW, Orlandi F, Barbato D, Tedesco M, Maina T, Nock BA, de Jong M. J Nucl Med (2017), volume 58, pp 293-299.
Neuroendocrine Tumor Therapy: 177Lu-DOTATATE
Mittra ES. Am J Roentgenol. (2018)
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group.
J Clin Oncol. (2018)
NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice
Kaloudi A, Lymperis E, Giarika A, Dalm S, Orlandi F, Barbato D, Tedesco M, Maina T, de Jong M, Nock BA. Molecules (2017), volume 22, 1950.
Clinical History of the Theranostic Radioisotope Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine
Levine R, Krenning EP. J Nucl Med (2017) volume 58, 3S-9S
Peptide receptor radioisotope therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): From literature to practice
Bournaud C, Kelly A, Hindié E, Tenenbaum F, Faivre-Chauvet A, Courbon F, Taïeb D, Dierickx LO, Coriat R, Ansquer C. Med Nuc (2017) volume 41, pp 42-54.
...